Details

Autor(en) / Beteiligte

• Zhong, Michael
• van der Walt, Anneke
• Stankovich, Jim
• Kalincik, Tomas
• Buzzard, Katherine
• Skibina, Olga
• Boz, Cavit
• Hodgkinson, Suzanne
• Slee, Mark
• Lechner-Scott, Jeannette
• Macdonell, Richard
• Prevost, Julie
• Kuhle, Jens
• Laureys, Guy
• Van Hijfte, Liesbeth
• Alroughani, Raed
• Kermode, Allan G
• Butler, Ernest
• Barnett, Michael
• Eichau, Sara
• van Pesch, Vincent
• Grammond, Pierre
• McCombe, Pamela
• Karabudak, Rana
• Duquette, Pierre
• Girard, Marc
• Taylor, Bruce
• Yeh, Wei
• Monif, Mastura
• Gresle, Melissa
• Butzkueven, Helmut
• Jokubaitis, Vilija G

Titel

Prediction of multiple sclerosis outcomes when switching to ocrelizumab

Ist Teil von

• Multiple sclerosis, 2022-05, Vol.28 (6), p.958-969

Ort / Verlag

London, England: SAGE Publications

Erscheinungsjahr

2022

Quelle

MEDLINE

Beschreibungen/Notizen

• Background: Increasingly, people with relapsing-remitting multiple sclerosis (RRMS) are switched to highly effective disease-modifying therapies (DMTs) such as ocrelizumab. Objective: To determine predictors of relapse and disability progression when switching from another DMT to ocrelizumab. Methods: Patients with RRMS who switched to ocrelizumab were identified from the MSBase Registry and grouped by prior disease-modifying therapy (pDMT; interferon-β/glatiramer acetate, dimethyl fumarate, teriflunomide, fingolimod or natalizumab) and washout duration (<1 month, 1–2 months or 2–6 months). Survival analyses including multivariable Cox proportional hazard regression models were used to identify predictors of on-ocrelizumab relapse within 1 year, and 6-month confirmed disability progression (CDP). Results: After adjustment, relapse hazard when switching from fingolimod was greater than other pDMTs, but only in the first 3 months of ocrelizumab therapy (hazard ratio (HR) = 3.98, 95% confidence interval (CI) = 1.57–11.11, p = 0.004). The adjusted hazard for CDP was significantly higher with longer washout (2–6 m compared to <1 m: HR = 9.57, 95% CI = 1.92–47.64, p = 0.006). Conclusion: The risk of disability worsening during switch to ocrelizumab is reduced by short treatment gaps. Patients who cease fingolimod are at heightened relapse risk in the first 3 months on ocrelizumab. Prospective evaluation of strategies such as washout reduction may help optimise this switch.